TCECUR Q2-19
Comment
2024-11-06
Comment on STENOCARE’s Q3-Report 2024
2024-10-23
Comment on Pharma Equity Group’s obtained patent protection in Japan for RNX-051
2024-10-14
Comment on STENOCARE’s Updated Guidance for 2024
2024-10-07
Comment on Pharma Equity Group’s Directed Share Issue to a Premium
Equity research report
2024-09-05
ODI Pharma